HLA-DRA Antikörper (AA 26-254)

Produktnummer ABIN7600950

Dieses Maus Monoklonal-Antikörper erkennt spezifisch HLA-DRA in WB, IHC und FACS. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für HLA-DRA Antikörper (AA 26-254) (ABIN7600950)

Target: HLA-DRA (HLA Class II DR alpha (HLA-DRA))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser HLA-DRA Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Flow Cytometry (FACS)

Klon: 8I10H1

Produktdetails anti-HLA-DRA Antikörper

Bindungsspezifität: AA 26-254

Verwendungszweck: Anti-HLA-DR/HLA-DRA Antibody Picoband® (monoclonal, 8I10H1)

Kreuzreaktivität (Details): No cross-reactivity with other proteins.

Produktmerkmale: Anti-HLA-DR/HLA-DRA Antibody Picoband® (monoclonal, 8I10H1) (ABIN7600950). Tested in Flow Cytometry, IHC, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Aufreinigung: Immunogen affinity purified.

Immunogen: E.coli-derived human HLA-DR/HLA-DRA recombinant protein (Position: I26-L254).

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Western blot, 0.25-0.5 μg/mL, Human
Immunohistochemistry(Paraffin-embedded Section), 2-5 μg/mL, Human
Flow Cytometry (Fixed), 1-3 μg/1x10⁶ cells, Human
1. Tjernlund U, Scheynius A, Johansson C, et al. (1989). "T-cell response to purified protein derivative after removal of Langerhans' cells from epidermal cell suspensions containing keratinocytes expressing class II transplantation antigens". Scand. J. Immunol. 28 (6): 667-73. 2. Chelladurai, M., Honn, K. V., Walz, D. A. HLA-DR is a procoagulant. Biochem. Biophys. Res. Commun. 178: 467-473, 1991. 3. Das, H. K., Lawrance, S. K., Weissman, S. M. Structure and nucleotide sequence of the heavy chain gene of HLA-DR. Proc. Nat. Acad. Sci. 80: 3543-3547, 1983.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Konzentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl and 0.2 mg Na2HPO4.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.

Details zu HLA-DRA

Target: HLA-DRA (HLA Class II DR alpha (HLA-DRA))

Andere Bezeichnung: HLA-DRA

Hintergrund:

Synonyms: Exportin-1, Exp1, Chromosome region maintenance 1 protein homolog, XPO1, CRM1

Tissue Specificity: Expressed in heart, brain, placenta, lung, liver, skeletal muscle, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocytes. Not expressed in the kidney.

Background: HLA class II histocompatibility antigen, DR alpha chainis aproteinthat in humans is encoded by the HLA-DRAgene. It is mapped to 6p21.32. HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5.

Molekulargewicht: 35-37 kDa

Gen-ID: 3122

UniProt: P01903

Pathways: T-Zell Rezeptor Signalweg, CXCR4-mediated Signaling Events, Human Leukocyte Antigen (HLA) in Adaptive Immune Response